

Pfizer Inc. (PFE)

NYSE; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0000078003

Pfizer Inc. PFE; healthcare	
Grade	E A B C D E weakest fifth of 371 graded peers percentile 96.2; sampling error 2.5 points; lower is stronger
Rank	357 of 371
Profitability	D percentile 73.7
Solvency	E percentile 86.0
Growth and financing	C/D percentile 61.8
Reliability	0.94 AUC filers with over \$2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025
Peer failure rate	0.52% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	over \$2.67B assets total assets \$208.2B
Standard universe	inside revenue above \$1M and assets above \$10M
Warnings	none active not computable: distress
Inputs computable	8 of 14
Graded from	filings received through Feb 26, 2026 225 days before the rescans; latest periodic filing 10-Q received Aug 4, 2026
Last close	\$27.83 2026-10-08; market equity \$158.6B
Price used in grade	None



E, the bear

weakest fifth of its sector; letters are fifths of the 371 graded peers

Share price, twelve months to the rescans

split-adjusted close; the letter is fixed at the rescans that set it



Rescans on file: D/E from Apr 21, 2023, E from May 21, 2023, D/E from Sep 21, 2023, E from Mar 21, 2024

Letter at every rescans

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Feb 26, 2026

section. In China, we expect to continue to face intense competition by certain generic manufacturers, which has resulted, and may result in the future, in price cuts and volume loss of some of our products. In addition, our patented products may face generic or biosimilar competition before patent-based and/or regulatory exclusivity expires, including from "at-risk" launch (despite pending patent infringement litigation against the generic or biosimilar product) by a manufacturer of a generic or biosimilar version of one of

our patented products.


The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 73.7						
Gross profitability		22.3%	32.2%	60.6	372	2025-12-31
Return on invested capital		not computable	9.3%			one or more required annual facts are missing
Accruals ratio		(1.9%)	(6.6%)	77.0	811	2025-12-31
Gross margin stability, five years		8.7 pts	2.8 pts	83.5	243	2025-12-31
Solvency, sleeve percentile 86.0						
Twelve-month failure probability		not computable	0.07%			latest liabilities, cash plus short-term investments, book equity, and shares are required
Altman Z double-prime		not computable	(0.31)			one or more required annual facts are missing
Net debt to EBITDA		not computable	1.82x			one or more required annual facts are missing
Interest coverage		not computable	(4.51x)			one or more required annual facts are missing
Current ratio		1.16x	2.96x	86.0	839	2025-12-31
Growth and financing, sleeve percentile 61.8						
Revenue growth, three-year compound		(14.8%)	10.0%	87.2	415	2025-12-31
Free cash flow growth, three-year compound		(29.6%)	10.9%	95.8	96	2025-12-31
Reinvestment rate		not computable	37.1%			one or more required annual facts are missing
Asset growth, three years		1.8%	2.1%	47.4	704	2025-12-31
Net share issuance, one year		0.3%	2.5%	16.7	634	2026-02-19

Among 371 peers

healthcare; letters are fifths of this list



Rank	Company	Percentile	Letter	Warnings
352	Silo Pharma, Inc. (SILO)	94.9	E	dilution, degenerate inputs, distress
353	VivoSim Labs, Inc. (VIVS)	95.1	E	dilution, short runway, late filer
354	ALX Oncology Holdings Inc. (ALXO)	95.4	E	dilution, short runway, degenerate inputs, fortress balance sheet
355	Biomerica Inc. (BMRA)	95.7	E	short runway
356	Bolt Biotherapeutics, Inc. (BOLT)	95.9	E	short runway, distress
357	Pfizer Inc. (PFE) <	96.2	E	
358	Dare Bioscience, Inc. (DARE)	96.5	E	dilution
359	Longeveron Inc. (LGVN)	96.8	E	short runway
360	Clene Inc. (CLNN)	97.0	E	dilution, distress
361	Agenus Inc. (AGEN)	97.3	E	dilution, short runway
362	Nektar Therapeutics (NKTR)	97.6	E	dilution, short runway

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	19.5%	8.0%	59
Distance from 52-week high	(4.1%)	(31.4%)	94
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	5.7%	(1.0%)	84
Book value to price	0.54	0.28	71
Sales to price	0.39	0.31	57
Composite equity issuance, five years	(26.2%)	20.3%	4
Relative strength against the sector, log excess return	(0.03)	(0.14)	59

Diagnostics

not in the grade

Measure	Value
Piotroski F-score 6 of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	pass
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	\$976.0M
Operating cash flow, four quarters	\$13.4B
Months of runway	not finite

Days since last periodic filing

66 (10-Q received Aug 4, 2026)

Median daily dollar volume, 63 sessions

\$946.2M

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:Revenues	\$62.6B	2025-12-31	2026-02-26	10-K	0000078003-26-000026
2	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$16.1B	2025-12-31	2026-02-26	10-K	0000078003-26-000026
3	assets	us-gaap:Assets	\$208.2B	2025-12-31	2026-02-26	10-K	0000078003-26-000026
4	net income	us-gaap:NetIncomeLoss	\$7.8B	2025-12-31	2026-02-26	10-K	0000078003-26-000026
5	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$11.7B	2025-12-31	2026-02-26	10-K	0000078003-26-000026
6	assets	us-gaap:Assets	\$213.4B	2024-12-31	2026-02-26	10-K	0000078003-26-000026
7	revenue	us-gaap:Revenues	\$63.6B	2024-12-31	2026-02-26	10-K	0000078003-26-000026
8	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$17.9B	2024-12-31	2026-02-26	10-K	0000078003-26-000026
9	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$50.9B	2023-12-31	2024-02-22	10-K	0000078003-24-000039
10	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$25.0B	2023-12-31	2026-02-26	10-K	0000078003-26-000026
11	revenue	us-gaap:Revenues	\$101.2B	2022-12-31	2025-02-27	10-K	0000078003-25-000054
12	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$34.3B	2022-12-31	2025-02-27	10-K	0000078003-25-000054
13	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$73.6B	2021-12-31	2024-02-22	10-K	0000078003-24-000039
14	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$30.8B	2021-12-31	2024-02-22	10-K	0000078003-24-000039
15	current assets	us-gaap:AssetsCurrent	\$42.9B	2025-12-31	2026-02-26	10-K	0000078003-26-000026
16	current liabilities	us-gaap:LiabilitiesCurrent	\$37.0B	2025-12-31	2026-02-26	10-K	0000078003-26-000026
17	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$2.6B	2025-12-31	2026-02-26	10-K	0000078003-26-000026
18	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$12.7B	2024-12-31	2026-02-26	10-K	0000078003-26-000026
19	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$2.9B	2024-12-31	2026-02-26	10-K	0000078003-26-000026
20	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$8.7B	2023-12-31	2026-02-26	10-K	0000078003-26-000026
21	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$3.9B	2023-12-31	2026-02-26	10-K	0000078003-26-000026
22	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$29.3B	2022-12-31	2025-02-27	10-K	0000078003-25-000054
23	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$3.2B	2022-12-31	2025-02-27	10-K	0000078003-25-000054
24	assets	us-gaap:Assets	\$226.5B	2023-12-31	2025-02-27	10-K	0000078003-25-000054
25	assets	us-gaap:Assets	\$197.2B	2022-12-31	2024-02-22	10-K	0000078003-24-000039
26	shares outstanding	dei:EntityCommonStockSharesOutstanding	5,686,267,431	2026-02-19	2026-02-26	10-K	0000078003-26-000026
27	shares outstanding	dei:EntityCommonStockSharesOutstanding	5,667,340,414	2025-02-20	2025-02-27	10-K	0000078003-25-000054